about
Effect on refractive outcomes after cataract surgery of intraocular lens constant personalization using the Haigis formula.Augmentation of macular pigment following supplementation with all three macular carotenoids: an exploratory study.The development of a public optometry system in Mozambique: a Cost Benefit Analysis.Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment.The impact of macular pigment augmentation on visual performance using different carotenoid formulations.Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration.Barriers to use of refractive services in MozambiqueFraming professional programs within development projects: driving longer term recognition and integration.Trail Making Test performance contributes to subjective judgment of visual efficiency in older adultsEvaluations of refraction competencies of ophthalmic technicians in Mozambique.Factors affecting the academic performance of optometry students in Mozambique.Visual Function and Its Relationship with Severity of Early, and Activity of Neovascular, Age-Related Macular DegenerationDevelopment of socially responsive competency frameworks for ophthalmic technicians and optometrists in Mozambique.Lower Macular Pigment Optical Density in Foveal-Involved Glaucoma.Open angle glaucoma effects on preattentive visual search efficiency for flicker, motion displacement and orientation pop-out tasks.Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab.Diagnostic sensitivity/specificity of preattentive vision tests in glaucoma.Macular pigment is associated with glare-affected visual function and central visual field loss in glaucoma.Macular pigment optical density in an ageing Irish population: The Irish Longitudinal Study on Ageing.The relationship between macular pigment and visual performance.Augmentation of macular pigment following implantation of blue light-filtering intraocular lenses at the time of cataract surgery.Clinical applicability of the Macular Degeneration Detection Device (MDD-2): a novel photostress recovery measurement device.Suitability and repeatability of a photostress recovery test device, the macular degeneration detector (MDD-2), for diabetes and diabetic retinopathy assessment.Macular Pigment Optical Density is Lower in Type 2 Diabetes, Compared with Type 1 Diabetes and Normal ControlsThe acceptability and visual impact of 0.01% atropine in a Caucasian population.Relationship between fear of falling and mobility varies with visual function among older adults.Estimation of effective lens position using a method independent of preoperative keratometry readings.Evidence of lower macular pigment optical density in chronic open angle glaucoma.An evaluation of a novel instrument for measuring macular pigment optical density: the MPS 9000.Surgically induced astigmatism after phacoemulsification with and without correction for posture-related ocular cyclotorsion: randomized controlled study.Prognostic Indicators and Outcome Measures for Surgical Removal of Symptomatic Nonadvanced CataractChanges in intraocular pressure and anterior segment morphometry after uneventful phacoemulsification cataract surgeryEffects of retinal image degradation on pre-attentive visual search (PAVS) efficiency for flicker, movement and orientation stimuliThe impact of macular pigment augmentation on visual performance in normal subjects: COMPASSMacular pigment: its associations with color discrimination and matchingImpact of dietary carotenoid deprivation on macular pigment and serum concentrations of lutein and zeaxanthinEducation is positively associated with macular pigment: the Irish Longitudinal Study on Ageing (TILDA)Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocolLow-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocolReply
P50
Q33627201-012B8CDC-E9D0-4A8C-B4C5-FBADE1BD6D56Q34108927-2DEA1965-FFFB-4443-9C10-6153FBBC160BQ34274413-AC134150-56BE-4E8D-8286-F11AF502EB4EQ34278325-DA185990-E1B7-4C06-8D60-8F88D809D0F6Q34310338-DAF5331A-E369-4809-8C2D-5833246216FBQ34422484-966B9031-DFF3-4C70-9D97-3CBAA4394D6EQ34759915-7C67A5F8-C955-45F7-B362-3DE7F011760EQ35994190-AF891003-F178-4AF5-BF4F-F500BB475CA3Q36361916-640EF8A3-986C-46F1-A6B9-232F99BC8D1BQ37014580-C29DB856-803B-4E60-948B-FDAD8D06C1CCQ38390026-EE78EC05-77D2-4011-AAE2-59265874B0FCQ38837386-2584F5AC-F96A-4FF4-8D0E-5C5A894CCFAFQ40183867-C21993F1-1D7C-4413-B1F4-5FD052F8FFFBQ40651813-FDFA9C9A-FB8D-4293-95DB-D6C8016C46DAQ40684485-EDFD1511-BEB5-462D-ACBF-1A2E06C8412AQ41206130-B5D52D9B-8A8E-4486-B697-11EB02FF0B2CQ42660981-02A89AD3-2EDA-4B3D-960B-D2BA8A6C59E0Q42695240-598381D9-D693-4BB6-9E70-F7FE9AD5BE69Q43047847-1B6B791B-7784-4E93-AD9B-E5CA59C87E2FQ43098301-11CA80AB-E8D3-45C3-A744-F0340815605BQ45921404-C30349F7-8472-4ED8-BADF-D6EA6CEE45F7Q46433854-BC961CE8-7C3C-48BA-B225-4253C621B76EQ46562369-B2EB1771-6D55-4729-BF07-DE3945DCE531Q46908829-D5F3701C-F224-4437-BC44-39063EBA7CC4Q47818216-A3B39726-3A12-4001-A1A5-E134BE4209FBQ47959200-B1C25FA7-FABC-40BC-B8A2-29F3ECC0C015Q51055388-16491A22-30EC-46F2-9EE2-0BAB1CD1D072Q51214822-352E215B-330F-4A46-B55A-C7C4EE86AC30Q51502474-58FF9126-749A-48DF-A8A8-B437217B852DQ51779638-D492CAED-7DF6-44C9-8B86-EDC4D3FBE022Q57244067-F31D2B1C-5F44-4F12-96A2-0B2428171AA0Q61646789-7CCCA9F4-0773-4FAC-B777-4998D3F68B2CQ80138084-03398AA3-CB0E-4F11-9885-F9A690B7E999Q83211085-D1C8C9B8-47D6-421C-9DA0-7BE0FAD9DE2EQ83818494-D8723AAC-9A0B-4D7B-A425-ACB78EAE075DQ85272562-4681FCB8-915D-4C17-9616-7EC251C33C3CQ85318176-4624261B-795C-4909-A2BD-C31AD165DAB9Q89458782-D0382290-CA9C-4C33-9565-EC465B79C3AEQ90949400-9EE1A80B-A53C-4235-B2A7-3EA4B56823F9Q95427762-14755678-0FE4-42E3-B9C2-C9DFABC86D35
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James Loughman
@ast
James Loughman
@en
James Loughman
@es
James Loughman
@nl
James Loughman
@sl
type
label
James Loughman
@ast
James Loughman
@en
James Loughman
@es
James Loughman
@nl
James Loughman
@sl
prefLabel
James Loughman
@ast
James Loughman
@en
James Loughman
@es
James Loughman
@nl
James Loughman
@sl
P106
P1153
14065115800
P21
P31
P496
0000-0003-3130-8991